CCN5 Protein Shows Promise in Preventing Cardiac Cellular Senescence

Cardiovascular diseases (CVD) remain the leading cause of death globally, and emerging research suggests that cellular senescence – a process where cells stop dividing and contribute to inflammation – plays a significant role in their development. A new study highlights the potential of the matricellular protein CCN5 (likewise known as WISP2) as a therapeutic strategy to combat cardiac cellular senescence and potentially leisurely the progression of CVD.

Understanding Cardiac Cellular Senescence

As we age, and due to cumulative cellular stress, cells can enter a state of senescence. Even as senescence can initially serve a protective role, senescent cells release harmful substances that promote inflammation and dysfunction in surrounding tissues. In the heart, this process contributes to structural remodeling and declining function. Identifying ways to limit or reverse cardiac cellular senescence is therefore a major focus of cardiovascular research.

How CCN5 Impacts Cardiac Cells

Researchers investigated whether CCN5, previously known for its anti-fibrotic properties in the heart, could directly influence cardiac cellular senescence. Their experiments, conducted on both H9c2 cardiac myoblasts (heart muscle cells) and cardiac fibroblasts (cells that support heart muscle), utilized key markers of senescence: p53 and p21 protein expression, senescence-associated β-galactosidase staining, and the presence of γH2AX foci, which indicate DNA damage. ¹

Suppressing Senescence and Inflammation

The study demonstrated that CCN5 effectively inhibited doxorubicin-induced cardiac cellular senescence in both cardiac myoblasts and fibroblasts. Doxorubicin is a chemotherapy drug known to cause cardiotoxicity and is often used in research to simulate stress-induced premature aging in heart cells. ¹

Importantly, CCN5 also disrupted the senescence-associated secretory phenotype (SASP). SASP is a pro-inflammatory signaling cascade where senescent cells promote dysfunction in neighboring tissues. CCN5 suppressed this harmful cross-talk between fibroblasts and myoblasts, suggesting it acts both within individual cells and by mitigating intercellular signaling that amplifies senescence. ¹

Restoring Cellular Function and Protecting Against Infarction

Beyond preventing senescence, CCN5 restored the apoptotic response in senescent cells, potentially allowing for the clearance of damaged cells. In a mouse model of myocardial infarction (heart attack), administering CCN5 attenuated the senescence induced by the infarction, demonstrating its relevance in a living organism. ¹

Future Directions and Clinical Potential

While these findings are promising, it’s important to note that the research was conducted in experimental models. Further studies are needed to validate these results in human trials and determine optimal dosing, delivery methods, and long-term safety. ²

If successfully translated to clinical practice, targeting cardiac cellular senescence with CCN5 could offer a novel approach to slowing structural changes and functional decline in individuals with cardiovascular disease. ²

Key Takeaways

• CCN5, a matricellular protein, demonstrates a significant ability to reduce cardiac cellular senescence.
• CCN5 impacts both the senescence process within individual cells and the harmful signaling between cells that exacerbates senescence.
• CCN5 may restore the natural process of cell death (apoptosis) in senescent cells, aiding in the removal of damaged tissue.
• Further research is needed to determine the clinical potential of CCN5 as a therapy for cardiovascular diseases.

Reference: Jo Y et al. The matricellular protein CCN5 (WISP2) inhibits cellular senescence in cardiac myoblasts and fibroblasts. Sci Rep. 2026; doi:10.1038/s41598-026-40206-1.